- Q1. What is the business of Molbio Diagnostics Limited ?It is an Indian molecular diagnostics firm that makes Truenat point-of-care PCR devices and test kits for rapid detection of infectious diseases like TB, COVID-19, HIV and more.
- Q2. Why is the company raising funds via IPO?Molbio Technologies is raising funds via IPO to raise capital for R&D facilities, a Centre of Excellence, and machinery upgrades for its manufacturing units, plus general corporate use.
- Q3. What is the size of the issue and where will it list?The issue size of the IPO comprises of ₹ 200 Cr as Fresh Issue + OFS ~1.26 Cr equity shares. It will be listed on BSE and NSE platform.
- Q4. What are the key risks to an investor?Key risks include high dependence on public healthcare/government contracts, customer concentration, and reliance on TB test revenues.
- Q5. What are the potential upsides?Upsides include strong global adoption of Truenat tech, recurring test kit sales, solid revenue growth and WHO recognition for key tests.
- Q6. How to apply for the IPO?Investors can apply for the IPO through ASBA via net banking or using UPI through registered stock brokers once the IPO opens for subscription.
Upcoming
Molbio Diagnostics Limited
0
IPO Score
0
*Score varies on actual price
Molbio Diagnostics Limited is an Indian medical diagnostics company that develops and manufactures point-of-care molecular diagnostic technologies, including its flagship Truenat platform – a portable, battery-operated PCR system used to deliver rapid test results (within about an hour) for infectious diseases such as tuberculosis (TB), COVID-19, HIV, HPV, and hepatitis B & C. It operates multiple manufacturing facilities in India and serves both domestic and international markets.
Molbio Diagnostics has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for an IPO consisting a Fresh Issue of ₹ 200 Crore and an Offer-for-Sale (OFS) of 12,556,000 Equity Shares by existing shareholders.
Molbio Diagnostics Limited was incorporated on 2000 & currently Mr. Sriram Natarajan serves as the Executive Director & Chief Executive Officer (CEO) of the company.
It is the Truenat point-of-care molecular diagnosis platform – a portable, battery-operated PCR system that provides rapid testing for infectious and selected non-communicable diseases.It has exported its Truenat platform to over 85 countries with over ~10,000 installations globally and has empowered diagnostics for 40 + million individuals.
Subscription date to apply for Molbio Diagnostics Limited is yet to be announced. Price band for the IPO is yet to be declared.
Revenue, PAT, EBITDA
|
Year
|
2025
|
|---|---|
|
Networth
|
₹ 952.94 Cr
|
|
Revenue
|
₹ 1020.41 Cr
|
|
EBITDA
|
₹ 256.63 Cr
|
|
PAT
|
₹ 138.57 Cr
|
|
EBITDA Margin
|
~24.97%
|
|
PAT Margin
|
~13.48%
|
|
Face Value
|
Rs.01 per Equity Share
|
IPO Important Dates
|
#
|
Date
|
|---|---|
|
Open Date
|
TBA
|
|
Close Date
|
TBA
|
|
Anchor Investor Bidding
|
TBA
|
|
Allotment Date
|
TBA
|
|
Refunds& Demat Credit
|
TBA
|
|
Tentative Listing Date
|
TBA
|
Use Of Proceeds
|
Purpose
|
Amount
|
|---|---|
|
Technology & Infrastructure
|
₹ 99.36 Cr
|
|
Purchasing Plant & Machinery
|
₹ 73.59 Cr
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
General Corporate Purpose
|
Balance
|
Financial Data
|
#
|
2023
|
2024
|
2025
|
|---|---|---|---|
|
Revenue (₹ Cr)
|
₹ 332.5
|
₹ 836.6
|
₹ 1,020.4
|
|
PAT (₹ Cr)
|
₹ -3.4
|
₹ 83.5
|
₹ 138.6
|
|
Asset (₹ Cr)
|
₹ 1,034.2
|
₹ 1,221.1
|
₹ 1,461.6
|
|
Net Worth (₹ Cr)
|
₹ 706.0
|
₹ 807.9
|
₹ 952.9
|
IPO Grey Market Premium
|
Date
|
IPO Price
|
IPO GMP
|
Profit Per Lot
|
|---|---|---|---|
|
08-Aug
|
₹ –
|
₹ –
|
₹ –
|
|
07-Aug
|
₹ –
|
₹ –
|
₹ –
|
|
06-Aug
|
₹ –
|
₹ –
|
₹ –
|
|
05-Aug
|
₹ –
|
₹ –
|
₹ –
|
|
04-Aug
|
₹ –
|
₹ –
|
₹ –
|
Promoters – Pre offer equity (Approx)
|
Promoters
|
% Shares
|
|---|---|
|
Exxora Trading LLP
|
~ 41.23 %
|
|
Dr. Chandrasekhar Bhaskaran Nair
|
~ 5.42 %
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
Lot Size details
|
Application Type
|
Lot Size
|
No. of Lot
|
No. of Shares
|
Investment Amount
|
|---|---|---|---|---|
|
Retail (Min)
|
–
|
1
|
–
|
₹ –
|
|
Retail (Max)
|
–
|
13
|
–
|
₹ –
|
|
HNI (Min)
|
–
|
14
|
–
|
₹ –
|
|
HNI (Max)
|
–
|
66
|
–
|
₹ –
|
|
Big HNI (Min)
|
–
|
67
|
–
|
₹ –
|
Key Performance Index (KPI)
|
ROE
|
00
|
|---|---|
|
ROCE
|
00
|
|
RoNW
|
00
|
JOIN OUR SOCIAL-MEDIA PLATFORMS TO STAY UPDATED
